Hydrapres (Hydralazine Hydrochloride)

Hydrapres (hydralazine hydrochloride) is indicated for the treatment of hypertension, particularly in cases where other antihypertensive agents are insufficient or contraindicated.

• Provides short‑term control of severe hypertension by rapidly lowering arterial pressure.
• Used as an adjunct in hypertensive emergencies to achieve prompt vasodilation.
• Added to combination therapy for resistant hypertension when monotherapy fails to achieve target blood pressure.
• May be employed in hypertension linked to chronic kidney disease to improve renal perfusion.
• Administered pre‑operatively to obtain rapid blood pressure reduction before surgical procedures.

• Hydralazine hydrochloride acts as a direct vasodilator by relaxing arteriolar smooth muscle. It interferes with calcium influx and inhibits inositol trisphosphate–mediated calcium release, leading to decreased intracellular calcium concentration. The resulting reduction in vascular smooth‑muscle tone lowers peripheral vascular resistance and produces a fall in arterial blood pressure independent of autonomic or hormonal pathways. The effect is dose‑dependent and reversible upon discontinuation.

Hydrapres may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common

• Headache, often mild to moderate in intensity and may improve with continued therapy.
• Facial flushing or a sensation of warmth, typically transient and most noticeable shortly after dosing.
• Tachycardia, presenting as a rapid heartbeat that can be accompanied by palpitations.
• Nausea and occasional vomiting, which are usually mild and resolve without intervention.

Serious

• Lupus‑like syndrome, characterized by joint pain, fever, rash, and serologic abnormalities resembling systemic lupus erythematosus.
• Severe hypotension that may lead to dizziness, fainting, or shock, requiring immediate medical attention.
• Reflex bradycardia, a paradoxical slowing of heart rate that can occur after an initial increase in pulse.

When prescribing Hydrapres, clinicians should consider several precautionary measures to ensure safe use.

• Assess cardiovascular status, especially for pre‑existing heart failure or coronary artery disease.
• Monitor blood pressure closely and carefully during initiation and dose adjustments.
• Use caution in patients with renal or hepatic impairment, adjusting dose as needed.
• Evaluate for a history of drug‑induced lupus or autoimmune disorders.
• Avoid abrupt discontinuation to prevent rebound hypertension.
• Counsel pregnant or nursing women that safety data are limited and risks may outweigh benefits.

Hydrapres can interact with other medications, potentially altering its efficacy or increasing adverse effects.

Avoid

• Concurrent use with other direct vasodilators (e.g., nitroglycerin) due to additive hypotensive risk.
• Combination with β‑blockers without careful monitoring, as reflex tachycardia may be blunted.
• Co‑administration with drugs that induce lupus-like syndrome (e.g., procainamide) may increase autoimmune risk.

Use with caution

• Concurrent use with diuretics may enhance antihypertensive effect and require dose adjustment.
• Combining with central α‑agonists (e.g., clonidine) may lead to unpredictable blood pressure changes.
• Use with MAO inhibitors should be monitored because of possible exaggerated vasodilatory response.